Personalis, Inc. provides genomic sequencing and analytics solutions. The Company supports the development of personalized cancer vaccines and other next-generation cancer immunotherapies. Personalis serves customers worldwide.

Current Report (Form 8-K | Period ending 2024-12-13)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Personalis Inc (PSNL US)

Current Report (Form 8-K | Period ending 2024-12-13)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-11-06)

Current Report (Form 8-K | Period ending 2024-09-18)

S-3 | Registration statement for specified transactions by certain issuers

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)